<code id='4E7DF03646'></code><style id='4E7DF03646'></style>
    • <acronym id='4E7DF03646'></acronym>
      <center id='4E7DF03646'><center id='4E7DF03646'><tfoot id='4E7DF03646'></tfoot></center><abbr id='4E7DF03646'><dir id='4E7DF03646'><tfoot id='4E7DF03646'></tfoot><noframes id='4E7DF03646'>

    • <optgroup id='4E7DF03646'><strike id='4E7DF03646'><sup id='4E7DF03646'></sup></strike><code id='4E7DF03646'></code></optgroup>
        1. <b id='4E7DF03646'><label id='4E7DF03646'><select id='4E7DF03646'><dt id='4E7DF03646'><span id='4E7DF03646'></span></dt></select></label></b><u id='4E7DF03646'></u>
          <i id='4E7DF03646'><strike id='4E7DF03646'><tt id='4E7DF03646'><pre id='4E7DF03646'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:fashion    Page View:75715
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In